A Randomized, Double-blind Pacebo-controlled Trial of Cardioprotective Effect of Platycodon Grandiflorum in Early Breast Cancer Patients Treated with Anthracycline-based Themotherapy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16009256

Enrollment

Unknown

Registered

2016-09-23

Start date

2015-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Intervention group:Platycodon Grandiflorum granules

Control group:Placebo

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Pathological diagnosis for breast cancer; (2) Patients received anthracycline-based themotherapy; (3) KPS score over 60; (4) Expect survival over 6 monthes; (5) Patients aged 20-70years; (6) No severe organic and functional disease; (7) No anthracycline-based chemotherapy history and more than 1 monthe not receiving chemotherapy. (8)Patients willing to paticipate the research and signe the informed consent file.

Exclusion criteria

Exclusion criteria: (1) Patients have a history of myocardial injury, CHD, myocardosis, cardiac functional insufficiency; (2) ALT, AST, Scr over trouble normal standard; (3) Patients with acute infection; (4) women with pregnancy, planned pregnancy or lactating; (5) Patients have other malingant tumor; (6) Allergic to this study drug; (7) Patients participated in other clinical trials.

Design outcomes

Primary

Measure	Time frame
Clinical Heart Failure;	—

Secondary

Measure	Time frame
Subclinical Heart Failure;	—

Countries

China

Contacts

Public ContactLiu Sheng

Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine

lshtcm@163.com+86 18917763005

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 26, 2026